Amgen Announces Voting Results of Annual Meeting of Stockholders

       Amgen Announces Voting Results of Annual Meeting of Stockholders

PR Newswire

THOUSAND OAKS, Calif., May 22, 2013

THOUSAND OAKS, Calif., May 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today
announced voting results from the Company's Annual Meeting of Stockholders,
held in Westlake Village, Calif. Approximately 87.80 percent of outstanding
shares were represented at the meeting.

The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A.
Bradway, Francois de Carbonnel, Vance D. Coffman, Robert A. Eckert, Rebecca M.
Henderson, Frank C. Herringer, Tyler Jacks, Gilbert S. Omenn, Judith C.
Pelham, Leonard D. Schaeffer and Ronald D. Sugar were each re-elected to
Amgen's Board of Directors. Each director received at least 89.51 percent of
the votes cast "For." J. Paul Reason (USN Retired) is retiring from the Board.
With the re-election of all of the director nominees, and the retirement of
Admiral Reason, Amgen currently has 13 directors.

With approximately 98.55 percent of the votes cast "For," stockholders
ratified Ernst & Young as Amgen's independent registered public accountants
for the year ending Dec. 31, 2013.

Stockholders approved, on an advisory basis, the named executive officer
compensation, commonly known as "Say-on-Pay." The non-binding proposal gives
stockholders the opportunity to endorse or not endorse Amgen's executive pay
programs and policies. Say-on-Pay received approximately 85.69 percent of the
votes cast "For" the proposal.

Stockholders approved the amendment and restatement of the Amgen Inc. 2009
Equity Incentive Plan (the "Amended Plan"). The Amended Plan increases the
authorized number of shares of Common Stock issuable under the plan and
satisfies stockholder approval requirements for performance-based awards under
the Internal Revenue Code. The Amended Plan was approved with approximately
81.89 percent of votes cast "For."

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. For more information, visit and follow
us on

Forward-Looking Statements
This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2012, and in any
subsequent periodic reports on Form 10-Q and Form 8-K. Amgen is providing
this information as of the date of this news release and does not undertake
any obligation to update any forward-looking statements contained in this
document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. The Company's results may be affected by
our ability to successfully market both new and existing products domestically
and internationally, clinical and regulatory developments (domestic or
foreign) involving current and future products, sales growth of recently
launched products, competition from other products (domestic or foreign),
difficulties or delays in manufacturing our products. In addition, sales of
our products are affected by reimbursement policies imposed by third-party
payors, including governments, private insurance plans and managed care
providers and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. Furthermore, our research, testing, pricing, marketing and
other operations are subject to extensive regulation by domestic and foreign
government regulatory authorities. We or others could identify safety, side
effects or manufacturing problems with our products after they are on the
market. Our business may be impacted by government investigations, litigation
and products liability claims. If we fail to meet the compliance obligations
in the corporate integrity agreement between us and the U.S. government, we
could become subject to significant sanctions. Further, while we routinely
obtain patents for our products and technology, the protection offered by our
patents and patent applications may be challenged, invalidated or circumvented
by our competitors. We depend on third parties for a significant portion of
our manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete with
other companies with respect to some of our marketed products as well as for
the discovery and development of new products. Discovery or identification of
new product candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that any
particular product candidate will be successful and become a commercial
product. Further, some raw materials, medical devices and component parts for
our products are supplied by sole third-party suppliers. Our business
performance could affect or limit our ability to repurchase our common stock
or the ability of the Amgen Inc. Board of Directors to declare a dividend.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)



Press spacebar to pause and continue. Press esc to stop.